Fig. 4From: Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adultsCD4 count over time. RPV rilpivirine, EFV efavirenz, PI protease inhibitorBack to article page